Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ANTX
#3609
AN2 Therapeutics, Inc. Common Stock
1.1
0
+1.85%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+1.85%
Monthly Change
-7.56%
6 month change
-3.51%
Year Change
+0.92%
Previous Close
1.0
8
Open
1.1
0
Bid
Ask
Low
1.1
0
High
1.1
0
Volume
1
Markets
US Stock Market
Healthcare
ANTX
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
TTM
Key stats
Total common shares outstanding
19.4 M
29.77 M
30.1 M
—
Valuation ratios
Enterprise value
161.39 M
575.94 M
20.14 M
68.74 M
Price to earnings ratio
-3.48
-7.25
-0.8
-3.67
Price to sales ratio
—
—
—
—
Price to cash flow ratio
4.46
8.8
0.84
3.97
Price to book ratio
1.56
3.76
0.5
0.86
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
0.4
0.47
0.56
0.01
Return on equity %
0.43
0.52
0.63
0.01
Return on invested capital %
2 741.62
1 425.16
1 149
—
Gross margin %
—
—
—
—
Operating margin %
—
—
—
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
13.72
7.87
10.07
43.56
Inventory turnover
—
—
—
—
Asset turnover
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
-2.18
-2.26
-1.65
-0.99
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
6.47
4.54
2.8
9.17
Net current asset value per share
6.43
4.68
2.89
9.56
Tangible book value per share
6.22
5.28
2.74
9.46
Working capital per share
5.96
4.09
2.6
8.66
Book value per share
6.22
5.28
2.74
9.46
News
AN2 Therapeutics appoints Sarah Williams as principal accounting officer
FDA clears IND for epetraborole trial in mycobacterium abscessus
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
An2 therapeutics (ANTX): cfo Day sells $8883 in shares
An2 therapeutics CSO prior sells $6507 in stock
Eizen, AN2 Therapeutics COO, sells $25k in ANTX stock
An2 therapeutics chief development officer sells $9k in stock
AN2 Therapeutics partners with GSK to develop TB treatments
Eizen Joshua M of AN2 Therapeutics sells $3213 in stock
Prior Stephen David, AN2 Therapeutics chief strategy officer, sells $872 in stock
AN2 Therapeutics doses first cohort in Phase 1 trial for Chagas disease